All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, after positive results in ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

and the neuromyelitis optica spectrum disorder therapy known as Uplizna. Combined, these drugs contributed to a $904 million boost in Amgen's total revenue. The acquisition drove 29% volume growth ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Beyond MariTide, Amgen's pipeline includes several other promising candidates: Uplizna: Recently showed favorable Phase III results for generalized myasthenia gravis (gMG) Rocatinlimab ...

Amgen shows strong clinical progress and financial resilience, but current valuations and technical indicators suggest caution, leading to a "hold" recommendation. Significant investments in ...

Thousand Oaks, California-based Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $142 billion ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...